[HTML][HTML] Adult B-cell acute lymphoblastic leukemia cells display decreased PTEN activity and constitutive hyperactivation of PI3K/Akt pathway despite high PTEN …

AM Gomes, MVD Soares, P Ribeiro, J Caldas… - …, 2014 - ncbi.nlm.nih.gov
Adult B-cell acute lymphoblastic leukemia remains a major therapeutic challenge, requiring
a better characterization of the molecular determinants underlying disease progression and …

Adult B-cell acute lymphoblastic leukemia cells display decreased PTEN activity and constitutive hyperactivation of PI3K/Akt pathway despite high PTEN protein levels …

AM Gomes, MV Soares, P Ribeiro, J Caldas… - …, 2014 - europepmc.org
Adult B-cell acute lymphoblastic leukemia remains a major therapeutic challenge, requiring
a better characterization of the molecular determinants underlying disease progression and …

[PDF][PDF] Adult B-cell acute lymphoblastic leukemia cells display decreased PTEN activity and constitutive hyperactivation of PI3K/Akt pathway despite high PTEN protein …

AM Gomes, MVD Soares, P Ribeiro, J Caldas, V Póvoa… - 2014 - researchgate.net
Adult B-cell acute lymphoblastic leukemia remains a major therapeutic challenge, requiring
a better characterization of the molecular determinants underlying disease progression and …

Adult B-cell acute lymphoblastic leukemia cells display decreased PTEN activity and constitutive hyperactivation of PI3K/Akt pathway despite high PTEN protein levels

AM Gomes, MV Soares, P Ribeiro, J Caldas… - …, 2014 - repositorio.ul.pt
Adult B-cell acute lymphoblastic leukemia remains a major therapeutic challenge, requiring
a better characterization of the molecular determinants underlying disease progression and …

[引用][C] Adult B-cell acute lymphoblastic leukemia cells display decreased PTEN activity and constitutive hyperactivation of PI3K/Akt pathway despite high PTEN protein …

AM Gomes, MVD Soares, P Ribeiro, J Caldas, V Povoa… - Haematologica, 2014 - cir.nii.ac.jp
Adult B-cell acute lymphoblastic leukemia cells display decreased PTEN activity and
constitutive hyperactivation of PI3K/Akt pathway despite high PTEN protein levels | CiNii …

[HTML][HTML] Adult B-cell acute lymphoblastic leukemia cells display decreased PTEN activity and constitutive hyperactivation of PI3K/Akt pathway despite high PTEN …

AM Gomes, MVD Soares, P Ribeiro, J Caldas… - …, 2014 - haematologica.org
Adult B-cell acute lymphoblastic leukemia remains a major therapeutic challenge, requiring
a better characterization of the molecular determinants underlying disease progression and …

Adult B-cell acute lymphoblastic leukemia cells display decreased PTEN activity and constitutive hyperactivation of PI3K/Akt pathway despite high PTEN protein levels

AM Gomes, MVD Soares, P Ribeiro… - …, 2014 - pubmed.ncbi.nlm.nih.gov
Adult B-cell acute lymphoblastic leukemia remains a major therapeutic challenge, requiring
a better characterization of the molecular determinants underlying disease progression and …

[PDF][PDF] Adult B-cell acute lymphoblastic leukemia cells display decreased PTEN activity and constitutive hyperactivation of PI3K/Akt pathway despite high PTEN protein …

AM Gomes, MVD Soares, P Ribeiro, J Caldas, V Póvoa… - 2014 - academia.edu
Adult B-cell acute lymphoblastic leukemia remains a major therapeutic challenge, requiring
a better characterization of the molecular determinants underlying disease progression and …

[PDF][PDF] Adult B-cell acute lymphoblastic leukemia cells display decreased PTEN activity and constitutive hyperactivation of PI3K/Akt pathway despite high PTEN protein …

AM Gomes, MVD Soares, P Ribeiro, J Caldas, V Póvoa… - 2014 - Citeseer
Adult B-cell acute lymphoblastic leukemia remains a major therapeutic challenge, requiring
a better characterization of the molecular determinants underlying disease progression and …

Adult B-cell acute lymphoblastic leukemia cells display decreased PTEN activity and constitutive hyperactivation of PI3K/Akt pathway despite high PTEN protein levels …

AM Gomes, MV Soares, P Ribeiro, J Caldas… - …, 2014 - europepmc.org
Adult B-cell acute lymphoblastic leukemia remains a major therapeutic challenge, requiring
a better characterization of the molecular determinants underlying disease progression and …